<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03153137</url>
  </required_header>
  <id_info>
    <org_study_id>AC-055H301</org_study_id>
    <nct_id>NCT03153137</nct_id>
  </id_info>
  <brief_title>Clinical Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Subjects</brief_title>
  <acronym>RUBATO</acronym>
  <official_title>Prospective, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study Assessing the Efficacy and Safety of Macitentan in Fontan-palliated Adult and Adolescent Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to assess the effect of macitentan 10 mg as compared to placebo on
      exercise capacity through cardiopulmonary exercise testing.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 7, 2017</start_date>
  <completion_date type="Anticipated">March 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">March 28, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in peak VO2 (oxygen uptake)</measure>
    <time_frame>16 weeks, i.e. from Baseline (Randomization/Visit 2) to Week 16 (Visit 4)</time_frame>
    <description>Change in peak VO2 (oxygen uptake)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in peak VO2</measure>
    <time_frame>52 weeks, i.e. from Baseline (Visit 2) over 52 weeks</time_frame>
    <description>Change in peak VO2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical activity measured by accelerometer</measure>
    <time_frame>16 weeks, i.e. from Baseline (Visit 2) to Week 16 (Visit 4)</time_frame>
    <description>Change in mean count per minute of daily physical activity measured by accelerometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-emergent AEs and SAEs</measure>
    <time_frame>at least 52 weeks, i.e. up to 30 days after study treatment discontinuation</time_frame>
    <description>Treatment-emergent AEs and SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough (pre dose) plasma concentrations</measure>
    <time_frame>at Week 8 (Visit 3) and Week 16 (Visit 4): 2 days OR at EOT in the case of premature study drug discontinuation: 1 day</time_frame>
    <description>Trough (pre dose) plasma concentrations</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Congenital Heart Disease</condition>
  <arm_group>
    <arm_group_label>Macitentan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Macitentan 10 mg per day; film-coated tablet; oral use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>film-coated tablet; oral use</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Macitentan 10 mg</intervention_name>
    <description>film-coated tablet; oral use</description>
    <arm_group_label>Macitentan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>film-coated tablet; oral use</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent/assent from the subject and/or a legal representative prior
             to initiation of any study-mandated procedures

          -  Fontan-palliated subjects with either intra-atrial lateral tunnel total cavopulmonary
             connection (LT-TCPC), or extra cardiac tunnel TCPC (EC-TCPC) surgery &gt; 1 year before
             Screening. Either LT- or EC-TCPC can be primary or secondary to atrio-pulmonary
             connection

          -  New York Heart Association (NYHA) functional class (FC) II or III (assessed by the
             investigator using the Specific Activity Scale

          -  Women of childbearing potential must have a negative serum pregnancy test use reliable
             contraception

        Exclusion Criteria:

          -  Pattern of Fontan circulation severity

          -  Deterioration of the Fontan-palliated condition.

          -  Limitations to Cardiopulmonary exercise testing (CPET)

          -  Peak VO2 &lt; 15 mL/kg/min.

          -  Any known factor or disease that may interfere with treatment compliance or full
             participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Children'S of Alabama - Pediatric Cardiovascular Services</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233-1935</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>205-934-0917</phone>
      <email>bpearce@peds.uab.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA/ Ahmanson Adult Congenital Heart Disease Ctr</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>310-825-5950</phone>
      <email>jaboulhosn@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital Heart Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>617-726-8510</phone>
      <email>ddo2@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nationwide Children'S Hosp</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>614-722-2700</phone>
      <email>Curt.Daniels@nationwidechildrens.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Children'S Hosp - Dept of Cardiology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-2303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>832-826-5600</phone>
      <email>wjf@bcm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>61882224000</phone>
      <email>pdisney@internode.on.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>61295157110</phone>
      <email>David.Celermajer@sswahs.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Prince Charles Hospital</name>
      <address>
        <city>Chermside</city>
        <zip>4032</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>0061073139 4111</phone>
      <email>Mugur.nicolae@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Children'S Hospital Melbourne, Cardiology</name>
      <address>
        <city>Parkville</city>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+61 3 9345 5781</phone>
      <email>yves.dudekem@rch.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lady Cilento Children'S Hosp, Qld Paediatric Cardiac Service</name>
      <address>
        <city>South Brisbane</city>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>61730681111</phone>
      <email>robert.justo@health.qld.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Copenhagen University Hospital, Cardio</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+45 3545 2018</phone>
      <email>lars.soendergaard.01@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hosp Cardiology Haut Leveque - Dept Congenital Diseases</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+33 5 57 65 64 65</phone>
      <email>jean-benoit.thambo@chu-bordeaux.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Berlin, Ped Cardiology</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>004930 4593 2800</phone>
      <email>berger@dhzb.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Birmingham Queen Elizabeth Hospital, Qe Medical Centre</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Principal Investigator</last_name>
      <phone>+44 121 371 4493</phone>
      <email>Paul.Clift@uhb.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2017</study_first_submitted>
  <study_first_submitted_qc>May 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macitentan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

